Renalytix (NASDAQ:RNLX – Get Free Report) and SomaLogic (NASDAQ:SLGC – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, profitability and dividends.
Earnings and Valuation
This table compares Renalytix and SomaLogic’s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Renalytix | $3.72 million | 29.67 | -$45.28 million | ($0.66) | -3.52 |
| SomaLogic | $101.39 million | 4.16 | -$109.16 million | ($0.75) | -2.99 |
Renalytix has higher earnings, but lower revenue than SomaLogic. Renalytix is trading at a lower price-to-earnings ratio than SomaLogic, indicating that it is currently the more affordable of the two stocks.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Renalytix | -1,375.46% | -255.70% | -122.73% |
| SomaLogic | -139.23% | -25.49% | -22.27% |
Risk and Volatility
Renalytix has a beta of 2.49, indicating that its stock price is 149% more volatile than the S&P 500. Comparatively, SomaLogic has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500.
Institutional & Insider Ownership
7.5% of Renalytix shares are owned by institutional investors. Comparatively, 66.3% of SomaLogic shares are owned by institutional investors. 21.6% of Renalytix shares are owned by insiders. Comparatively, 14.9% of SomaLogic shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of recent recommendations for Renalytix and SomaLogic, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Renalytix | 0 | 0 | 2 | 0 | 3.00 |
| SomaLogic | 0 | 0 | 3 | 0 | 3.00 |
Renalytix presently has a consensus price target of $5.00, indicating a potential upside of 115.05%. SomaLogic has a consensus price target of $6.75, indicating a potential upside of 201.34%. Given SomaLogic’s higher probable upside, analysts clearly believe SomaLogic is more favorable than Renalytix.
Summary
SomaLogic beats Renalytix on 8 of the 13 factors compared between the two stocks.
About Renalytix
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.
About SomaLogic
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various biological samples for protein biomarker signatures, which are utilized in drug discovery and development. Its SomaScan's biomarker discoveries use in diagnostic applications for various diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal, a laboratory-developed test. It serves pharmaceutical and biotechnology companies, and academic and government research institutions. The company has a collaboration agreement with Illumina Cambridge, Ltd for the development of co-branded NGS-based proteomic distributable kits. The company was founded in 1999 and is headquartered in Boulder, Colorado.
Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.
